Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > A summary of my thoughts

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Sep 27, 2021 4:57pm

145 Views

Post# 33925742

RE:A summary of my thoughts

Paul did mention a few times that he would like or be open to in- licensing another drug .
I think greater success with the existing drugs is needed before being able to have others rely on THTX to handle dales of one or more of their drugs,,,,,but I do like the concept

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing